Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Stimulering för att förbättra minnet (STIM)

29 juni 2026 uppdaterad av: Benjamin Hampstead, PhD, University of Michigan

Testar högupplöst transkraniell likströmsstimulering (HD-tDCS) som behandling av mild kognitiv funktionsnedsättning

Denna studie kommer att testa effekterna av olika doser av en form av icke-invasiv hjärnstimulering för behandling av individer med mild kognitiv funktionsnedsättning (MCI) och demens av Alzheimers typ (DAT).

Studieöversikt

Detaljerad beskrivning

Denna forskningsstudie görs för att lära sig viktig information om effekterna av svag elektrisk stimulering på hjärnans funktion hos personer med mild kognitiv funktionsnedsättning (MCI) och demens av Alzheimers typ (DAT). Resultaten kommer att hjälpa till att bestämma "hur mycket" stimulering som behövs för att förbättra minnet och tankeförmågan, hur det påverkar hjärnans funktion och vem som är mest sannolikt att dra nytta av det. I slutändan kan denna information vägleda behandlingsinsatser för personer i olika stadier av Alzheimers sjukdom. Studien kommer att använda hjärnavbildning för att se om dessa behandlingar förändrar hur deltagarna lär sig och kommer ihåg information. Funktionell magnetisk resonanstomografi (fMRI) och positronemissionstomografi (PET) kommer att användas. Studien kommer också att använda kognitiva tester och frågeformulär för att undersöka om deltagarnas minne (och relaterade förmågor) förändras på grund av behandlingen. Studien kommer att registrera deltagare med diagnosen MCI eller DAT. Det förväntas men inte krävs att deltagare kommer att vara medinskrivna i University of Michigan Memory and Aging Project (UM-MAP; HUM00000382).

Studietyp

Interventionell

Inskrivning (Faktisk)

233

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48105
        • University of Michigan

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

55 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Beskrivning

Inklusionskriterier:

  1. Diagnos av mild kognitiv funktionsnedsättning (MCI) eller demens av Alzheimers typ (DAT)
  2. Måste vara MRT-kompatibla, kriterier som även gäller för högupplöst transkraniell likströmsstimulering (HD-tDCS; t.ex. frånvaro av metalliska eller elektroniska implantat i överkroppen eller huvudet)
  3. Stabil på relevanta mediciner i minst 4 veckor före studieinskrivning

Exklusions kriterier:

  1. Vissa neurologiska sjukdomar
  2. Vissa psykiatriska tillstånd
  3. Svår känselnedsättning

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Sham Comparator: Sham-stimulering
Sham (placebo) dos av HD-tDCS-behandling i 30 minuter, i mellan 5-30 sessioner.
Deltagarna kommer att få sken (placebo) HD-tDCS i 30 minuter, för mellan 5-30 sessioner.
Experimentell: 1 mA Doseringsstimulering
1 milliAmp dos av HD-tDCS-behandling i 30 minuter, för mellan 5-30 sessioner.
Deltagarna kommer att få HD-tDCS vid 1 mA i 30 minuter, i mellan 5-30 sessioner.
Experimentell: 2 mA Doseringsstimulering
2 milliAmp dos av HD-tDCS-behandling i 30 minuter, för mellan 5-30 sessioner.
Deltagarna kommer att få HD-tDCS vid 2 mA i 30 minuter, i mellan 5-30 sessioner.
Experimentell: 3 mA Doseringsstimulering
3 milliAmp dos av HD-tDCS-behandling i 30 minuter, för mellan 5-30 sessioner.
Deltagarna kommer att få HD-tDCS vid 3 mA i 30 minuter, i mellan 5-30 sessioner.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Lateral Temporal Cortex Connectivity
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Primary outcome focuses on default mode network (DMN) between-network functional connectivity because the lateral temporal cortex is a core component of the DMN. Between-network functional connectivity is estimated from fMRI data as strength of temporal coupling between the DMN and other high-level (association) brain networks. For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) computed between DMN regions and other regions of the association cortex defined using standard functional atlas. Higher values reflect stronger functional connectivity between DMN and other regions. A Z-score's range is infinite. Expected value is between -3 to 3. Analyses conducted separately for amyloid negative (A-) and amyloid positive (A+) participants. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Self-Report of Contentment With Memory
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The Multifactorial Memory Questionnaire (MMQ) consists of three scales measuring separate aspects of metamemory. Items are rated on a 5-point Likert scale (0-4) based on the test taker's experiences over the previous two weeks.

MMQ-Satisfaction (formerly called MMQ-Contentment) scale measures satisfaction, concern, and overall appraisal of one's own memory. Each of 18 statements is rated based on degree of agreement. The score range is 0 to 72, with higher scores indicating a higher degree of satisfaction.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Self-Report of Memory Mistakes
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Multifactorial Memory Questionnaire (MMQ) Ability Score - This scale measures self-perception of everyday memory ability. Respondents rate how often they experienced each of 20 common memory mistakes over the previous two weeks. The score range is 0 to 80, with higher scores indicating better self-reported memory ability.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Self-Report of Memory Strategies Used
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Multifactorial Memory Questionnaire (MMQ) Strategies Score - This scale measures the use of practical memory strategies and aids in day-to-day life. Respondents rate how often they used each of 19 memory strategies over the previous two weeks. The score range is 0 to 76, with higher scores indicating greater use of memory strategies.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Change in Memory Functioning
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition. The delayed memory section is a measure of delayed recall and recognition for verbal and visual information. It includes the subtests List Recall, List Recognition, Story Memory, and Figure Recall. Low scores on this index indicate difficulties with recognition and retrieval of information from long-term memory stores This index is composed of both auditory and visual measures; therefore, a severe deficit in language, auditory processing, or visual functioning may impact one of the measures more than the other. Analysis included the sum of the raw scores for each of the delayed memory subtests, with possible scores ranging from 0 to 62. Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Change in Overall Fluid Cognitive Abilities
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Cognitive function was determined using the NIH Toolbox-Cognition Battery computerized tests, specifically the Fluid composite score. It is derived by averaging the subtests in the Fluid domain to achieve an overall standard score. Fully Corrected T-scores are adjusted for for age, gender, race/ethnicity, and educational attainment. The score compares the score of the participant to those in the NIH Toolbox nationally representative normative sampling. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Working Memory Effects of HD-tDCS Across Treatment Sessions
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The n-back test is a working memory task where participants identify stimulus that matches stimulus experienced "n" steps back. Participants performed a 2-back test, in which they were asked to remember and press a button when shown a stimulus that appeared 2 steps before the current one (e.g. square, circle, square).

The number of correct and incorrect identifications are normalized (z-score). Total score is the z-score of correct button presses minus the z-score of incorrect button presses. A higher score (d') reflects better working memory performance. Possible scores range from -4.85 to 4.85. Positive change (increase) in 2-back score across treatment sessions indicates improvement in working memory performance. Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y=n-back score.

Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Memory Accuracy Effects of HD-tDCS Across Treatment Sessions
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Paired Associates task is a verbal memory task that asks participants to learn a list of word pairs. After a delay, participants are shown correct and mismatched word pairs one at a time and asked to identify if the displayed word pair was from the list they were asked to learn or not.

Total accuracy is a proportion (total correct responses divided by total trials completed) ranging from 0 to 1 that measures the accuracy of a participant's responses to both correct and mismatched word pairs. Higher scores indicate better verbal memory performance, and positive changes over time indicate an improvement in verbal memory performance, measured after baseline (Session 1) and every intervention session (Sessions 2-5)

Data is shown as the mean slope calculation of participants across first 5 days of treatment and across all treatments, x=days of treatment, y= total accuracy.

Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Memory Sensitivity Effects of HD-tDCS Across Daily Sessions
Tidsram: Baseline
Verbal memory performance for computerized Paired Associates task, summarized with a computational model (linear ballistic accumulator decision model). The model uses each participant's accuracy and reaction times across trials to estimate how efficiently they accumulate information to distinguish previously studied (target) word pairs from new (lure) pairs. Reported outcome is the average memory sensitivity score at baseline, expressed as unitless model values (scores on a scale) where higher scores indicate better discrimination, scores near zero indicate chance-level performance, and negative scores (if present) indicate performance worse than chance.
Baseline
Tolerability of HD-tDCS
Tidsram: Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks); values represent mean symptom burden averaged across all post-stimulation assessments
Tolerability was assessed using the HD-tDCS Safety Questionnaire, an 11-item symptom checklist. The questionnaire assesses the presence (yes/no) of 10 specific self-reported symptoms (Itching, Burning, Tingling, Scalp Pain, Trouble Concentrating, Sleep problems, Headache, Mood Change, Neck Pain, and Other symptoms) and 1 oberserved symptom, Skin Redness. Skin Redness was excluded from this analysis as it is not related to the participant's perception of tolerability. The total score (symptom burden) was calculated by summing the number of symptoms present across the 10 items for each session. Score range: 0 to 10 symptoms, where 0 = no symptoms present and 10 = all symptoms present. Higher scores indicate worse tolerability (more symptoms experienced). Values represent the mean number of symptoms per session, calculated by averaging symptom burden scores across all post-stimulation assessments within each treatment group.
Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks); values represent mean symptom burden averaged across all post-stimulation assessments
Effectiveness of Blinding of HD-tDCS
Tidsram: Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks)
Participant's perception of treatment assignment assessed after each stimulation session using a 3-category ordinal scale. Participants guessed whether they received: (0) Sham stimulation, (1) Don't Know, or (2) Active stimulation. The scale is ordinal with Sham < Don't Know < Active. Effective blinding is indicated by no significant difference in the distribution of perceived assignment between active and sham groups (i.e., participants in active groups cannot reliably distinguish their treatment from sham). Higher proportional odds ratios would indicate active group participants were more likely to guess "active"; lower ratios would indicate sham participants were more likely to guess "active" (paradoxical pattern suggesting convincing sham condition).
Assessed immediately after each HD-tDCS session (participants received up to 30 sessions over approximately 1-12 weeks)
Change in Default Mode Network Connectivity
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The outcome focuses on default mode network (DMN) within-network functional connectivity. Within-network functional connectivity is estimated from fMRI data as strength of temporal coupling within DMN regions (nodes). For each participant and time point, correlation-based connectivity (Pearson r; Fisher r-to-z transformed; arbitrary units) was computed between DMN regions defined using a standard functional atlas. Higher values reflect stronger functional connectivity within DMN. A Z-score's range is infinite. Expected value is around -3 to 3. Analyses are conducted separately for amyloid negative (A-) and amyloid positive (A+) participants.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Cumulative Cognitive Change Across Daily Consecutive Sessions
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Measured through change in Cogstate or other comparable computerized cognitive testing scores across consecutive daily sessions.
Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).
Change in Global Cognition
Tidsram: Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

The Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) is a comprehensive neuropsychological battery for the evaluation of global cognition and has been validated in subjects with mild cognitive impairment, moderate to severe traumatic brain injuries, vascular dementias, and Alzheimer's disease. Data was analyzed using the sum of the subtest raw scores, which is an indicator of the general cognitive functioning of the examinee. Low scores suggest general cognitive impairment even when some individual subtest scores may be within normal limits. Individuals with low scores on this measure exhibit problems with attention, memory, language, and construction skills. Possible scores range from 0 to 321.

Post Intervention data collection was on day 5 of treatment. Post-Expansion (PE) appointments were not consecutive. Mean time between enrollment and PE was 10 wks, longest was 43 wks.

Change from Baseline to Post-Intervention (after tDCS Session 5 - day 5 of treatment) and from Baseline to Post-Expansion (after the participant's final tDCS session beyond Session 5, up to 43 weeks).

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Förändring i hämningsförmåga
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
A priori avsikt att mäta genom förändring i NIH Toolbox Flanker Inhibitory Control and Attention Test Score
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Förändring i konceptualiseringsförmåga
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
A priori avsikt att mäta genom förändring i NIH Toolbox Dimensional Change Card Sort Test Score
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Ändra i bildsekvensminnet
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
A priori avsikt att mäta genom förändring i NIH Toolbox Picture Sequence Memory Test Score
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Förändring i arbetsminnesförmåga
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
A priori avsikt att mäta genom förändring i NIH Toolbox List Sorting Working Memory Test Score
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Ändring i bearbetningshastighet
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
A priori avsikt att mäta genom förändring i NIH Toolbox Pattern Comparison Processing Speed ​​Test Score
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Förändring i Visuospatial funktion
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Mätt genom förändring i RBANS Visuospatial Index-poäng
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Ändring av språkfunktion
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Mätt genom förändring i RBANS språkindexpoäng
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Förändring i uppmärksamhet
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Mätt genom förändring i RBANS Attention Index-poäng
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Ändring i minnesfunktion
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Mätt genom förändring i RBANS Immediate Memory Index-poäng
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
Förändring i kognitiv funktion
Tidsram: Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)
A priori avsikt att mäta genom förändringar i RBANS deltestresultat
Baslinje och post-intervention (efter tDCS-sessioner 5 och 30)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Benjamin Hampstead, PhD, Associate professor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 april 2019

Primärt slutförande (Faktisk)

6 december 2024

Avslutad studie (Faktisk)

19 december 2024

Studieregistreringsdatum

Först inskickad

11 mars 2019

Först inskickad som uppfyllde QC-kriterierna

13 mars 2019

Första postat (Faktisk)

14 mars 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera